Indian Heart Journal (Dec 2018)

Transcatheter aortic valve replacement in India—Early experience, challenges, and outcomes from a single center

  • Sengottuvelu Gunasekaran,
  • Muthukumaran C. Sivaprakasam,
  • Vinodh kumar PaulPandi,
  • Abraham Oomman,
  • Asha Mahilmaran,
  • Mathew Samuel Kalarickal,
  • Vijay Shankar Sadhasivam,
  • Ganapathy Arumugam Chandrasekaran,
  • Srinivasan Kanthallu Narayanamoorthy,
  • Pramod Kumar Karaimbil Puthukavi,
  • Sathyamurthy Immaneni,
  • Rajeshwari Nayak,
  • Louis Felix Sridhar,
  • Paul Jude Ramesh Thangaraj,
  • Sunder Thirugnanasambandan,
  • Yusuf Meerangham Mohammed,
  • Dheeraj Reddy,
  • Dilip Kumar Mishra,
  • Girinath Malligayil Ramakrishna

Journal volume & issue
Vol. 70
pp. S347 – S352

Abstract

Read online

Background: Despite the increasing popularity of transcatheter aortic valve replacement (TAVR), only about 10,000 TAVR cases have been performed in Asia to date. The procedure is still in a nascent stage in India with very few centers offering this state-of-art technique. Here, we present the early results of TAVR experience at our center. Methods: Forty-nine patients with severe symptomatic aortic stenosis (AS) were referred to our center for TAVR from November 2015 to February 2018. Twenty-five patients underwent TAVR at our conventional cardiac catheterization laboratory under local or general anesthesia, with standby surgical team support. Results: The mean age of the patients was 72.0 ± 8.1 years. The mean Society of Thoracic Surgeons score was 13.8 ± 10.2. Baseline mean ejection fraction was 50.3 ± 14.8%. Baseline mean aortic valve gradient was 55.8 ± 24.7 mmHg. There was one procedural-related death. Two of the patients required urgent surgery: one for contained annular rupture and one underwent vascular repair for femoral artery occlusion. Mild and moderate paravalvular leak was seen in 11 and 3 patients, respectively. Four patients (16%) required permanent pacemaker. Eighty percent were in New York Heart Association class I-II at discharge. One-year all-cause mortality was 8%, with no hospitalizations or major adverse cardiac event during the 1-year follow-up. Conclusion: Our early data clearly shows that in our country, TAVR is a good alternative for symptomatic severe AS for high surgical risk cases. Large-scale multicenter studies are required to study the real impact of TAVR in the Indian scenario. During initial years of implementation of a nationwide TAVR program, it may be prudent to focus on creating TAVR Centers of Excellence by developing an ideal hub and spokes model. Keywords: Transcatheter aortic valve replacement (TAVR), Aortic stenosis, Indian experience